Electromedical Technologies Announces Financial and Operational Highlights for the Three and Six Months Ended June 30, 2022

SCOTTSDALE, Ariz., Aug. 18, 2022 Electromedical Technologies, Inc. (OTCQB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain by using frequencies and electro-modulation, is pleased to provide its Financial and Operational Highlights for the three and six months ended June 30, 2022.

"We continue to drive toward scalable growth and new innovations, positioning the Company as an emerging leader in technologies that offer a drug-free path to a pain-free life," noted Matthew Wolfson, Founder and CEO of Electromedical. "Q2 delivered another quarter of robust growth in net sales. And we made significant progress in board governance and product development."

Financial Performance Highlights for the Three Months Ended June 30, 2022

• Net Sales increased 11% over Q2 2021 to $225k primarily due to increased unit sales.
• Gross Margin increased to 80% as compared to 75% in Q2 2021.
• Loss from operations was ($283K) versus ($525K) in Q2 2021, an 85% improvement.
• Net loss was ($536K) versus ($775K) in Q2 2021, a 31% improvement, reflecting increased gross profit and reductions in selling, general and administrative expenses and interest.

Financial Performance Highlights for the Six Months Ended June 30, 2022

• Net Sales increased 21% year over the six months ended June 30,2021 to $447K.
• Gross Margin remained at 75% for both six-month periods.
• Loss from operations was ($672K) versus ($1.2M) in the six months ended June 30, 2021, a 46% improvement.
• Net loss was ($1.7M) versus ($3.3M) in the six months ended June 30,2021, a 49% improvement, reflecting increased gross profit and reductions in selling, general and administrative expenses and interest.

The Company's business model remained resilient during the quarter ended June 30 despite macro headwinds, including inflation, a slowdown in consumer spending, and continued global supply chain concerns. During the quarter, Electromedical was able to achieve top and bottom-line growth at improved margins, shrinking the Company's loss from operations by over 50% year over year, moving the Company closer to EBITDA profitability.

The Company continues to invest in expanding its sales and marketing resources as well as developing next-generation technology capable of providing scalable accelerating growth in the months and quarters ahead.

The Company was also able to shore up its balance sheet during the quarter by working with one of its most significant stakeholders to reduce debt carried by the Company by more than $600k in a debt-to-equity conversion involving restricted shares.

In addition, the Company added strong talent and experience to its Board of Directors with the addition of Lee Benson, a proven leader with an established track record of profound success in business and the engineering space.

Wolfson added, "We have reduced dilution risk, shored up the balance sheet, and added proven leadership talent to our board, building governance and strategic value into the core of the Company as we move toward scaling the business. We have a number of updates in the works related to R&D achievements and further investments in driving expanding sales. I look forward to providing additional updates soon."

About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief. 

For more information, please visit www.electromedtech.com.

Note: Nonhuman preliminary studies that we are planning to start in the near future and their applications are not related to our current product in any way and are currently not cleared in the US.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Corporate Contact:
Electromedical Technologies, Inc.
Iconic
Tel: 1.888.880.7888
Email: ir@electromedtech.com
https://electromedtech.com

 

1) 
Public Relations:
EDM Media, LLC
https://edm.media

 

 

ELECTROMEDICAL TECHNOLOGIES, INC.
BALANCE SHEETS
(UNAUDITED)
		March 31, 2022			December 31, 2021
ASSETS
Current assets:
Cash and cash equivalents		$	170,048		$	383,170
Accounts receivable			31,790			35,085
Inventories			196,924			218,510
Prepaid expenses and other current assets			24,930			38,002
Total current assets			423,692			674,767
Property and equipment, net			721,875			727,344
Total assets		$	1,145,567		$	1,402,111
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable		$	274,251		$	214,785
Credit cards payable			14,686			11,283
Accrued expenses and other current liabilities			539,237			317,037
Customer deposits			21,850			—
Convertible promissory notes, net of discount of $492,877 and    $723,166, respectively			1,289,476			811,687
Related party notes payable			—			57,875
Long term debt, current portion			30,490			29,502
Total current liabilities			2,169,990			1,442,169
Long-term liabilities:
Bank debt, net of current portion			511,613			518,849
Government debt, net of current portion			153,789			154,429
Other liabilities			9,204			9,167
Total liabilities			2,844,596			2,124,614
Commitments and contingencies (Note 9)			—			—
Stockholders' deficit
Series A Preferred Stock, $.00001 par value, 1,000,000 shares      authorized and 500,000 outstanding			355,000			355,000
Series B Preferred Stock, $.00001 par value, 1 share authorized and 0      outstanding			—			—
Common stock, $.00001 par value, 500,000,000 and 250,000,000      shares authorized;104,955,567 and 87,725,842 shares outstanding      at March 31, 2022 and December 31, 2021, respectively			1,048			876
Additional paid-in-capital			20,401,493			20,804,333
Accumulated deficit			(22,456,570)			(21,882,712)
Total stockholders' deficit			(1,699,029)			(722,503)
Total liabilities and stockholders' deficit		$	1,145,567		$	1,402,111

a)  The accompanying notes are an integral part of these financial statements

 

 

ELECTROMEDICAL TECHNOLOGIES, INC.
STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31,
(UNAUDITED)
		2022				2021
Net sales		$		221,894		$		166,440
Cost of sales				67,641				41,951
Gross profit				154,253				124,849
Selling, general and administrative expenses				879,810				1,689,383
Loss from operations				(725,557)				(1,564,534)
Other income (expense)
Interest expense				(213,379)				(1,060,302)
Change in fair market value of derivative liabilities				—				14,798
Other income (expense)				—				(428)
Loss on extinguishment of debt				(205,600)				—
Forgiveness of debt				—				50,082
Total other expense				(418,979)				(995,850)
Net loss		$		(1,144,536)		$		(2,560,384)
Deemed dividend related to warrant resets				(63,381)				(510,222)
Net loss attributable to common stockholders				(1,207,917)				(3,070,606)
Weighted average shares outstanding - basic and diluted				97,260,915				28,558,027
Weighted average loss per share - basic and diluted		$		(0.01)		$		(0.11)

b)  The accompanying notes are an integral part of these financial statements

 

 

 

ELECTROMEDICAL TECHNOLOGIES, INC.
STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT
FOR THE THREE MONTHS ENDED MARCH 31, 2022
(UNAUDITED)
																																		Total
		Series A Preferred								Series B Preferred								Common Stock								Paid in				Accumulated				Stockholders'
		Amount						Shares		Amount						Shares		Amount						Shares		Capital				Deficit				Deficit
Balance, December 31, 2021		$				355,000		500,000		$				—		—		$				876		87,725,842		$		20,804,333		$		(21,882,712)		$		(722,503)
Shares issued for consulting services						—		—						—		—						106		10,600,000				356,794				—				356,900
Warrants issued in conjunction with convertible promissory notes						—		—						—		—						—		—				142,996				—				142,996
Warrants reset in conjunction with convertible promissory notes						—		—						—		—						—		—				63,381				(63,381)				—
Adoption of ASU 2020-06						—		—						—		—						—		—				(1,013,414)				634,059				(379,355)
Issuance of common stock for cash						—		—						—		—						15		1,500,000				42,751				—				42,766
Cashless warrant exercises						—		—						—		—						51		5,129,725				(51)				—				—
Stock-based compensation						—		—						—		—						—		—				4,703				—				4,703
Net loss						—		—						—		—						—		—				—				(1,144,536)				(1,144,536)
Balance, March 31, 2022		$				355,000		500,000		$				—		—						1,048		104,955,567		$		20,401,493		$		(22,456,570)		$		(1,699,029)

 

The accompanying notes are an integral part of these financial statements

 

 

ELECTROMEDICAL TECHNOLOGIES, INC.
STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT
FOR THE THREE MONTHS ENDED MARCH 31, 2021
(UNAUDITED)
																										Total
		Preferred Stock								Common Stock								Paid in				Accumulated				Stockholders'
		Amount						Shares		Amount						Shares		Capital				Deficit				Deficit
Balance, December 31, 2020		$				355,000		500,000		$				269		27,175,800		$		7,957,860		$		(9,631,732)		$		(1,318,603)
Shares issued for consulting services						—		—						11		1,084,120				693,815				—				693,826
Warrant issued in conjunction with convertible promissory note						—		—						—		—				420,096				—				420,096
Warrants reset in conjunction with convertible promissory notes						—		—						—		—				510,222				(510,222)				—
Conversion of convertible promissory notes						—		—						10		1,019,113				380,093				—				380,103
Stock-based compensation						—		—						11		1,100,000				604,890				—				604,901
Net loss						—		—						—		—				—				(2,560,384)				(2,560,384)
Balance, March 31, 2021		$				355,000		500,000						301		30,379,033		$		10,566,976		$		(12,702,338)		$		(1,780,061)

The accompanying notes are an integral part of these financial statements

 

 

ELECTROMEDICAL TECHNOLOGIES, INC.
STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31,
(UNAUDITED)
		2022				2021
Cash flows from operating activities:
Net loss		$		(1,144,536)		$		(2,560,384)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense				361,603				1,298,727
Depreciation and amortization				5,469				5,469
Forgiveness of debt				—				(49,783)
Loss on extinguishment of debt				205,600				—
Amortization of debt discount and day one derivative loss and warrant expense				164,710				1,010,601
Change in fair value of derivative liabilities- convertible promissory notes				—				(14,798)
Change in operating assets and liabilities:
Accounts receivable				3,295				(4,178)
Inventories				21,586				(129,791)
Prepaid expenses and other current assets				13,072				161,990
Other assets				—				7,000
Accounts payable				59,466				(42,284)
Credit cards payable				3,403				(1,057)
Accrued expenses and other current liabilities				(33,400)				9,817
Customer deposits				21,850				(18,301)
Other liabilities				37				(265)
Net cash used in operating activities				(317,845)				(327,237)
Cash flows from financing activities:
Repayments on bank debt				(6,888)				(6,556)
Related party notes payable-net				(57,875)				(50,000)
Issuance of convertible promissory notes				494,220				712,500
Repayments on convertible promissory notes				(367,500)				—
Repayments on notes payable				—				(12,846)
Issuance of common stock for cash - net				42,766				—
Net cash provided by financing activities				104,723				643,098
Net (decrease) increase in cash and cash equivalents				(213,122)				315,861
Cash and cash equivalents, beginning of period				383,170				264,913
Cash and cash equivalents, end of period		$		170,048		$		580,774
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest		$		72,308		$		16,356
Income taxes		$		—		$		—
Non-cash investing and financing activities:
January 1,2022 adoption of ASU2020-06		$		379,355		$		—
Warrants, common stock and beneficial conversion feature issued in conjunction with convertible      promissory notes		$		192,996		$		420,096
Derivative liabilities issued in conjunction with convertible promissory notes		$		—		$		974,931
Conversion of convertible promissory notes, derivative liabilities and accrued interest into shares of      common stock		$		—		$		380,103

 

View original content:https://www.prnewswire.com/news-releases/electromedical-technologies-announces-financial-and-operational-highlights-for-the-three-and-six-months-ended-june-30-2022-301608542.html

SOURCE Electromedical Technologies, Inc